APLT Quote, Financials, Valuation and Earnings

Palatin Technologies has a net margin of -56222.13% compared to Applied Therapeutics's net margin of -2357.27%. Applied Therapeutics's return on equity of -797.82% beat Palatin Technologies's return on equity of --.

Applied Therapeutics has a consensus price target of $5.50, signalling upside risk potential of 906.59%. On the other hand Palatin Technologies has an analysts' consensus of $7.00 which suggests that it could grow by 764.09%. Given that Applied Therapeutics has higher upside potential than Palatin Technologies, analysts believe Applied Therapeutics is more attractive than Palatin Technologies.

Applied Therapeutics has a beta of 1.881, which suggesting that the stock is 88.052% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.793, suggesting its less volatile than the S&P 500 by 20.66%.

Applied Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Applied Therapeutics pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Applied Therapeutics quarterly revenues are $122K, which are smaller than Palatin Technologies quarterly revenues of $350K. Applied Therapeutics's net income of -$68.6M is lower than Palatin Technologies's net income of -$2.4M. Notably, Applied Therapeutics's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Applied Therapeutics is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Reviva Pharmaceuticals Holdings has a net margin of -56222.13% compared to Applied Therapeutics's net margin of --. Applied Therapeutics's return on equity of -797.82% beat Reviva Pharmaceuticals Holdings's return on equity of --.

Applied Therapeutics has a consensus price target of $5.50, signalling upside risk potential of 906.59%. On the other hand Reviva Pharmaceuticals Holdings has an analysts' consensus of $12.14 which suggests that it could grow by 1003.9%. Given that Reviva Pharmaceuticals Holdings has higher upside potential than Applied Therapeutics, analysts believe Reviva Pharmaceuticals Holdings is more attractive than Applied Therapeutics.

Applied Therapeutics has a beta of 1.881, which suggesting that the stock is 88.052% more volatile than S&P 500. In comparison Reviva Pharmaceuticals Holdings has a beta of -0.095, suggesting its less volatile than the S&P 500 by 109.539%.

Applied Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Reviva Pharmaceuticals Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Applied Therapeutics pays -- of its earnings as a dividend. Reviva Pharmaceuticals Holdings pays out -- of its earnings as a dividend.

Applied Therapeutics quarterly revenues are $122K, which are larger than Reviva Pharmaceuticals Holdings quarterly revenues of --. Applied Therapeutics's net income of -$68.6M is lower than Reviva Pharmaceuticals Holdings's net income of -$8.4M. Notably, Applied Therapeutics's price-to-earnings ratio is -- while Reviva Pharmaceuticals Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Applied Therapeutics is -- versus -- for Reviva Pharmaceuticals Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Cassava Sciences has a net margin of -56222.13% compared to Applied Therapeutics's net margin of --. Applied Therapeutics's return on equity of -797.82% beat Cassava Sciences's return on equity of --.

Applied Therapeutics has a consensus price target of $5.50, signalling upside risk potential of 906.59%. On the other hand Cassava Sciences has an analysts' consensus of -- which suggests that it could grow by 4072.66%. Given that Cassava Sciences has higher upside potential than Applied Therapeutics, analysts believe Cassava Sciences is more attractive than Applied Therapeutics.

Applied Therapeutics has a beta of 1.881, which suggesting that the stock is 88.052% more volatile than S&P 500. In comparison Cassava Sciences has a beta of -1.240, suggesting its less volatile than the S&P 500 by 224.042%.

Applied Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cassava Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Applied Therapeutics pays -- of its earnings as a dividend. Cassava Sciences pays out -- of its earnings as a dividend.

Applied Therapeutics quarterly revenues are $122K, which are larger than Cassava Sciences quarterly revenues of --. Applied Therapeutics's net income of -$68.6M is lower than Cassava Sciences's net income of -$27.6M. Notably, Applied Therapeutics's price-to-earnings ratio is -- while Cassava Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Applied Therapeutics is -- versus 3.15x for Cassava Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Verastem has a net margin of -56222.13% compared to Applied Therapeutics's net margin of -82.56%. Applied Therapeutics's return on equity of -797.82% beat Verastem's return on equity of -120.71%.

Applied Therapeutics has a consensus price target of $5.50, signalling upside risk potential of 906.59%. On the other hand Verastem has an analysts' consensus of $12.57 which suggests that it could grow by 73.88%. Given that Applied Therapeutics has higher upside potential than Verastem, analysts believe Applied Therapeutics is more attractive than Verastem.

Applied Therapeutics has a beta of 1.881, which suggesting that the stock is 88.052% more volatile than S&P 500. In comparison Verastem has a beta of 0.605, suggesting its less volatile than the S&P 500 by 39.46%.

Applied Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Verastem offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Applied Therapeutics pays -- of its earnings as a dividend. Verastem pays out -- of its earnings as a dividend.

Applied Therapeutics quarterly revenues are $122K, which are smaller than Verastem quarterly revenues of $10M. Applied Therapeutics's net income of -$68.6M is lower than Verastem's net income of -$24M. Notably, Applied Therapeutics's price-to-earnings ratio is -- while Verastem's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Applied Therapeutics is -- versus -- for Verastem. Usually stocks with elevated PS ratios are considered overvalued.